Wessel Due F is a drug from the group of agents that influence the processes of tissue metabolism and, in particular, blood clotting. It is a direct acting anticoagulant, characterized by a powerful antithrombotic, as well as fibrinolytic and capillary-protective action.
Release form and composition
The medicine has two forms of release:
- Solution for intramuscular and intravenous administration;
- Soft gelatin capsules.
The active substance is sulodexide. In one capsule it contains 250 lipoprotein lipase units (LU), in one milliliter of solution - 300 LU.
The composition of the gelatin capsule Wessel Due F, in addition to the active component, includes a number of auxiliary substances: colloidal silicon dioxide, sodium lauryl sarcosinate, triglycerides. For the manufacture of the shell are used: gelatin, glycerol, titanium dioxide (E171), sodium ethyl paraoxybenzoate, red iron oxide (E172), sodium propyl paraoxybenzoate (E171).
The composition of the solution Wessel Due f, except sulodexide, includes water for injection and sodium chloride.
- In the form of capsules - 25 pcs. in blisters, 2 blisters in a carton box;
- In the form of a solution - in ampoules of dark glass, 2 ml, 10 ampoules in a cardboard box.
Indications for use
According to the instructions to Wessel Due F, the indications for use of the drug are:
- Angiopathies (vascular pathologies), in which the patient has a high likelihood of blood clots (including angiopathies that developed against the background of myocardial infarction);
- Impaired blood circulation in the brain (including in the acute period of ischemic stroke, as well as in the early stages of recovery after it);
- Dyscirculatory encephalopathy, which is a consequence of atherosclerotic vascular disease, diabetes mellitus, or arterial hypertension;
- Vascular dementia (i.e. dementia due to cerebral vascular disease);
- Occlusive peripheral arterial disease associated with atherosclerosis or diabetes mellitus;
- Flebopathic syndrome;
- The presence of blood clots in the deep veins;
- Damage to the walls of the smallest blood vessels (including neuro, retino-nephropathy);
- Diabetic macroangiopathies (for example, encephalopathy, diabetic foot or cardiopathy);
- Thrombophilia (a condition characterized by an increased risk of developing recurrent vascular thrombosis of various localization) and antiphospholipid syndrome (in these pathologies, according to the instructions, Wessel Due F is prescribed in combination with acetylsalicylic acid, and also following low molecular weight heparins).
Since the use of Wessel Due F does not cause and does not aggravate the course of thrombotic thrombocytopenia provoked by the use of heparin (or “white thrombus syndrome”), it is also allowed to be used for the treatment of this pathological condition.
According to the instructions, Wessel Due F is contraindicated:
- With hemorrhagic diathesis;
- In diseases that are accompanied by a worsening of blood clotting;
- Patients with hypersensitivity to its components;
- Women in the first 13 weeks of pregnancy.
Dosing and Administration
At the initial stages of treatment, Vessel Due F is recommended to be injected parenterally into a muscle or into a vein (by bolus or drip method). Single dose - 2 ml (the contents of one ampoule). The duration of treatment is from 15 to 20 days.
To prepare the solution for intravenous infusion, 2 ml of the solution is diluted in 150-200 ml of sterile saline.
Upon completion of the injection course, the patient is transferred to the oral form of the drug. The standard scheme involves daily intake of 250 LU (one capsule) twice a day (between meals) for 30-40 days.
A full course of therapy is carried out at least twice a year.
The Wessel Due F dosing regimen can be revised (both in terms of dose and frequency of administration) based on the results of a qualitative diagnostic examination of the patient.
According to the annotation to the drug, the use of Wessel Due F may be accompanied by:
- Disorders of the digestive tract, which are expressed in the form of pain in the epigastric region, nausea, vomiting;
- Allergic reactions, manifested skin rash of various localization;
- Local reactions - pain, burning sensation, the appearance of a hematoma at the injection site.
According to medical reviews, if you exceed the recommended dose, Wessel Due F may cause bleeding or bleeding. Treatment of overdose involves the abolition of the drug and the conduct of symptomatic therapy.
Sulodexide should not be used in combination with direct or indirect anticoagulants, as well as with antiplatelet agents. Other clinically significant drug interactions of this tool have not been identified.
During the period of application of Vessel Due F, constant monitoring of the coagulogram is necessary. At the initial stages of treatment and prior to the completion of therapy, the following indicators should be evaluated: activated partial thromboplastin time (APTT), antithrombin III concentration, blood clotting time and bleeding time. It should be borne in mind that while taking this medicine, the normal APTT indices increase approximately 1.5 times.
Influence on ability to steer the vehicle and difficult mechanisms the drug does not render.
The generic Wessel Due F is Angioflux, also available in capsule and solution form for intramuscular and intravenous administration.
A similar mechanism of action is characterized by: Antithrombin III human, Anfibra, Heparin, Gemapaksan, Kleksan, Piyavit, Medical leech, Fraxiparin, Fragmin, Cybor 2500 and Cybor 3500, Fluxum, Enixum.
Terms and conditions of storage
Wessel Due F is a prescription drug on List B. It should be stored at a temperature not exceeding 30 ºС. Shelf life - 5 years.